Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how many S2 funding applications were approved in (1) NHS Bedfordshire, Luton and Milton Keynes Integrated Care Board, and (2) NHS Hertfordshire and West Essex Integrated Care Board, in (a) 2019, (b) 2020, (c) 2021, and (d) 2022.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England administers the Planned Treatment Scheme (S2) for residents of England. The Integrated Care Boards (Establishment) Order 2022 legally established 42 integrated care boards (ICB) with effect from 1 July 2022, therefore the following table can only provide information for two ICB’s showing the number of S2’s approved. Exact numbers have not been provided to prevent the identification of individual patients.
| Number of S2’s approved between 1 July 2022 to 31 December 2022 |
NHS Bedfordshire, Luton and Milton Keynes Integrated Care Board | Five or less |
NHS Hertfordshire and West Essex Integrated Care Board | Five or less |
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what support is available for people suffering from corticobasal degeneration.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Patients with a diagnosis of corticobasal degeneration would be supported through the usual range of commissioned health and social care services. Depending on the needs of an individual, support may be provided through a range of commissioned health and social care services including their general practitioner, general neurology services, specialised neurology services and social care. There is not a separately commissioned service for this condition.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what support is available for people with progressive supranuclear palsy.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Patients with a diagnosis of progressive supranuclear palsy would be supported through the usual range of commissioned health and social care services. Depending on the needs of an individual, support may be provided through a range of commissioned health and social care services including their general practitioner, general neurology services, specialised neurology services and social care. There is not a separately commissioned service for progressive supranuclear palsy.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how many people were diagnosed with corticobasal degeneration in (1) 2018, (2) 2019, (3) 2020, (4) 2021, and (5) 2022.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Congenital Anomaly and Rare Diseases Registration Services (NCARDRS) does not hold comprehensive data on corticobasal degeneration. Therefore, this this information is not available in the format requested.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, for each year since 2017, how many people have been diagnosed with progressive supranuclear palsy.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
National Congenital Anomaly and Rare Disease Registration Service (NCARDRS) does not hold comprehensive data on progressive supranuclear palsy, therefore this information is not available in the format requested. The Department funds research into rare diseases through the National Institute for Health and Care Research (NIHR). The usual practice of NIHR is not to ring-fence funds for expenditure on particular topics such on the causes and treatment of progressive supranuclear palsy. Research proposals in all areas compete for the funding available.
In the past five years the NIHR has funded a study into progressive supranuclear palsy with a total award value of £1,200,000. In the last five years the NIHR has further supported the delivery of over 40 studies relating to progressive supranuclear palsy via the NIHR infrastructure which includes research on potential causes and treatments.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what funding is being directed annually to researching the causes and treatment of progressive supranuclear palsy.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
National Congenital Anomaly and Rare Disease Registration Service (NCARDRS) does not hold comprehensive data on progressive supranuclear palsy, therefore this information is not available in the format requested. The Department funds research into rare diseases through the National Institute for Health and Care Research (NIHR). The usual practice of NIHR is not to ring-fence funds for expenditure on particular topics such on the causes and treatment of progressive supranuclear palsy. Research proposals in all areas compete for the funding available.
In the past five years the NIHR has funded a study into progressive supranuclear palsy with a total award value of £1,200,000. In the last five years the NIHR has further supported the delivery of over 40 studies relating to progressive supranuclear palsy via the NIHR infrastructure which includes research on potential causes and treatments.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how much money they are directing annually to research the (1) causes, and (2) treatment, for corticobasal degeneration.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department funds research through the National Institute for Health and Care Research (NIHR). While the NIHR have not provided programme funding for studies into corticobasal degeneration over the past five years, the NIHR has supported the delivery of 25 studies relating to corticobasal degeneration via the NIHR infrastructure.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how many clinically extremely vulnerable and immunocompromised people are living in the England.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
During the early phase of the COVID-19 pandemic, patients deemed to be clinically extremely vulnerable patients were advised to shield or take extra precautions. The success of the COVID-19 vaccination programme has meant that people who were part of this patient cohort are no longer at substantially greater risk than the general population and so are advised to follow the same guidance as everyone else on staying safe and preventing the spread of COVID-19 and other respiratory infections.
The definition and number of clinically extremely vulnerable and immunocompromised population has evolved as patients are diagnosed or complete treatment courses that remove their vulnerability.
However, there remains a smaller number of people whose weakened immune system means they may be at higher risk of serious illness from COVID-19, despite vaccination. This cohort remain a priority for the Government and as such, are offered enhanced protections such as treatments, booster vaccines, free lateral flow tests and public health advice.
The current assessment of the population in England at higher risk for COVID and therefore eligible for assessment for COVID-19 therapeutic treatments options is 2.5 to 3 million patients.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the effectiveness of Evusheld 2 in protecting clinically extremely vulnerable and immunocompromised people against COVID-19; and whether there are plans for it to be made available on the NHS.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) has made no evaluation of Evusheld 2. Should such an application be received, the MHRA will review this for quality, safety and effectiveness and the overall benefit risk. The MHRA, together with independent advisory groups, continues to review the emerging body of evidence regarding potential medicines for the prevention or treatment of COVID-19.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what measures they are taking to protect clinically extremely vulnerable and immunocompromised people from COVID-19.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
As set out in the Written Ministerial Statement on 30 March 2023, in 2023/24 the Government will maintain a range of capabilities to protect those at higher risk of severe illness from COVID-19. Given the continued effectiveness of vaccines and improved treatments, for most people there is a much lower risk of severe illness compared to earlier in the pandemic.
Appropriate levels of testing will remain to support diagnosis for clinical care and treatment and to protect very high-risk individuals and settings. Those who are clinically extremely vulnerable and immunocompromised are part of the group who are eligible for COVID-19 treatments in the community, enabling them easy access to anti-viral treatments. High risk individuals are also part of the priority cohort in line for booster vaccines. The Government will continue to consider the advice of the Joint Committee on Vaccination and Immunisation on future vaccine selection and booster programmes for those at greatest risk.
The Government will also maintain essential COVID-19 surveillance activities in the community, primary and secondary care, and in high-risk settings.